CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
IMGC936drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04622774
NCT04622774Phase 2Completed
CompareCT.gov

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors

ImmunoGen, Inc.·interventional·Posted Nov 10, 2020·Updated Jan 15, 2025

In Brief

A Phase 2 clinical trial evaluating IMGC936 for Advanced Solid Tumor. Completed, enrolled 56 participants across 13 sites in 3 countries.

Detailed Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesItaly, Spain, United States
CollaboratorsMacroGenics

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 10, 2020
Enrollment StartOct 29, 2020
Primary CompletionDec 28, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.6 years ago

Interventions

IMGC936drug

Antibody Drug Conjugate